AU2001249792A1 - Topical compositions containing prostaglandin E1 - Google Patents

Topical compositions containing prostaglandin E1

Info

Publication number
AU2001249792A1
AU2001249792A1 AU2001249792A AU4979201A AU2001249792A1 AU 2001249792 A1 AU2001249792 A1 AU 2001249792A1 AU 2001249792 A AU2001249792 A AU 2001249792A AU 4979201 A AU4979201 A AU 4979201A AU 2001249792 A1 AU2001249792 A1 AU 2001249792A1
Authority
AU
Australia
Prior art keywords
accordance
topical composition
composition
penetration enhancer
prostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249792A
Other languages
English (en)
Inventor
Nadir Buyuktimkin
Servet Buyuktimkin
James L. Yeager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexmed Holdings Inc
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of AU2001249792A1 publication Critical patent/AU2001249792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2001249792A 2000-04-04 2001-04-04 Topical compositions containing prostaglandin E1 Abandoned AU2001249792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09542668 2000-04-04
US09/542,668 US6414028B1 (en) 1997-11-05 2000-04-04 Topical compositions containing prostaglandin E1
PCT/US2001/010699 WO2001074279A1 (en) 2000-04-04 2001-04-04 Topical compositions containing prostaglandin e¿1?

Publications (1)

Publication Number Publication Date
AU2001249792A1 true AU2001249792A1 (en) 2001-10-15

Family

ID=24164793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249792A Abandoned AU2001249792A1 (en) 2000-04-04 2001-04-04 Topical compositions containing prostaglandin E1

Country Status (16)

Country Link
US (1) US6414028B1 (pt)
EP (1) EP1278495A4 (pt)
JP (1) JP2004514646A (pt)
KR (1) KR20030060769A (pt)
CN (1) CN1203895C (pt)
AU (1) AU2001249792A1 (pt)
BR (1) BR0109863A (pt)
CA (1) CA2405293A1 (pt)
HK (1) HK1059558A1 (pt)
HU (1) HUP0302452A2 (pt)
IL (1) IL152084A0 (pt)
MX (1) MXPA02009798A (pt)
NZ (1) NZ522363A (pt)
TR (1) TR200202308T2 (pt)
WO (1) WO2001074279A1 (pt)
ZA (1) ZA200208803B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6673841B2 (en) * 2001-12-20 2004-01-06 Whan In Pharm. Co., Ltd. Alprostadil alkyl ester-containing composition for external application
WO2003070281A1 (en) * 2002-02-15 2003-08-28 Nexmed (Holdings), Inc. Prostaglandin composition for the treatment of erectile dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
JP2006520792A (ja) * 2003-03-21 2006-09-14 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物によるニューロン生育の増強および方法
WO2004084861A2 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Angiogenesis promotion by prostaglandin compositions and methods
CA2520347A1 (en) * 2003-04-02 2004-10-21 Nexmed Holdings, Inc. Prostaglandin compositions and their use for the treatment of vasospasm
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
US20050113274A1 (en) * 2003-11-22 2005-05-26 Nadir Buyuktimkin Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
CA2645073A1 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
JP5297631B2 (ja) * 2007-11-13 2013-09-25 花王株式会社 皮膚外用組成物
WO2010039251A1 (en) 2008-10-03 2010-04-08 Nexmed Holdings, Inc. Stabilized composition for treating psoriasis
EP2566325A4 (en) * 2010-05-04 2014-06-11 Nexmed Holdings Inc COMPOSITIONS OF THERAPEUTIC AGENTS WITH SMALL MOLECULES
JP2014510156A (ja) 2011-04-07 2014-04-24 ネクスメッド ホールディングス，インコーポレイテッド レイノー病を治療する方法および組成物
ITRM20120036A1 (it) 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.
EP4117624A1 (en) * 2020-03-11 2023-01-18 AdvanSix Resins & Chemicals LLC Surfactants for healthcare products

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK243084A (da) 1983-05-26 1984-11-27 Takeda Chemical Industries Ltd Perkutane farmaceutiske praeparater til udvortes brug
GB8416638D0 (en) 1984-06-29 1984-08-01 Beecham Group Plc Topical treatment and composition
US4732892A (en) 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
US4771004A (en) 1986-08-29 1988-09-13 Iprx, Inc. Method for in vitro determination of transdermal absorption
US4808414A (en) 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US4865848A (en) 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5534260A (en) 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
JP3202777B2 (ja) 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
DK1473031T3 (da) 1993-12-13 2008-10-20 Avanir Pharmaceuticals Sucroseester - C20 til C28 alkoholformuleringer
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
NZ509618A (en) * 1998-08-20 2003-09-26 3M Innovative Properties Co A patch-in-a-bottle that provides a fluid composition, which is applied to a surface and subsequently dries to form a covering, such as a patch
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Also Published As

Publication number Publication date
TR200202308T2 (tr) 2005-07-21
EP1278495A4 (en) 2006-03-22
HUP0302452A2 (hu) 2003-11-28
JP2004514646A (ja) 2004-05-20
WO2001074279A1 (en) 2001-10-11
BR0109863A (pt) 2004-09-28
NZ522363A (en) 2004-12-24
ZA200208803B (en) 2003-12-19
HK1059558A1 (en) 2004-07-09
CN1449270A (zh) 2003-10-15
IL152084A0 (en) 2003-05-29
EP1278495A1 (en) 2003-01-29
KR20030060769A (ko) 2003-07-16
CA2405293A1 (en) 2001-10-11
MXPA02009798A (es) 2003-05-27
CN1203895C (zh) 2005-06-01
US6414028B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
US6414028B1 (en) Topical compositions containing prostaglandin E1
EP1028708B1 (en) Topical compositions for prostaglandin e1 delivery
ZA200505321B (en) Topical stabilized prostaglandin E compound dosage forms
US5795916A (en) Composition of external preparation
US4847260A (en) Composition for percutaneous administration
KR19990087477A (ko) 완충된 오르쏘 에스테르 중합체를 포함하는 약학 조성물
EP0600395A1 (en) Antinflammatory and analgesic diclofenac gel preparation
CZ102797A3 (cs) Sloučeniny na bázi omega-aminokyselin, způsob jejich přípravy jejich použití jako akcelerantů transdermální penetrace a akceleranty transdermální penetrace těmito sloučeninami tvořené
JPH0611715B2 (ja) 経皮吸収促進剤およびこれを含有する外用剤
CA2442479C (en) Topical compositions for prostaglandin e1 delivery
EP0309624B1 (en) Composition for enhancing percutaneous administration of medicine
JP3098275B2 (ja) トルナフテート含有液剤
EP2340016A2 (en) Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate
JPH07112960A (ja) Ｎ−置換−ｏ−トルイジン誘導体及びその塩、及びそれを有効成分として含有する薬物溶解剤